Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT03795311	TitleEvaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)	Phase Phase 1, Phase 2	Date Added 2019-01-07	Location France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs FOLFIRINOX Bevacizumab	Tags MSS/ MMRp
NCT ID NCT03785249	TitlePhase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1	Phase Phase 1	Date Added 2018-12-24	Location Alabama, United States Alaska, United States Arizona, United States California, United States Colorado, United States Connecticut, United States Delaware, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maine, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Puerto Rico	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs afatinib, cetuximab, MRTX849, Pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03783403	TitleA Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers	Phase Phase 1	Date Added 2018-12-21	Location Alabama, United States Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs CC-95251, cetuximab, Rituximab	Tags MSS/ MMRp
NCT ID NCT03772561	TitlePhase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies	Phase Phase 1	Date Added 2018-12-11	Location Singapore	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs AZD5363+Olaparib+Durvalumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03745326	TitleAdministering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients	Phase Phase 1, Phase 2	Date Added 2018-11-19	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Aldesleukin, anti-KRAS G12D mTCR PBL, Cyclophosphamide, Fludarabine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03740256	TitleBinary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors	Phase Phase 1	Date Added 2018-11-14	Location Texas, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs CAdVEC	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03727763	TitleCetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)	Phase Phase 2	Date Added 2018-11-01	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs cetuximab, Vemurafenib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03711058	TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer	Phase Phase 1, Phase 2	Date Added 2018-10-18	Location Maryland, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Copanlisib, Nivolumab	Tags MSS/ MMRp
NCT ID NCT03692429	TitlealloSHRINK – Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells	Phase Phase 1	Date Added 2018-10-02	Location Florida, United States Belgium	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs CYAD-101, FOLFIRI, FOLFOX	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03673787	TitleA Trial of Ipatasertib in Combination With Atezolizumab	Phase Phase 1	Date Added 2018-09-17	Location United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Atezolizumab, Ipatasertib	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 211 to 220 of 299 entries